Europe sells pomalidomide as Imnovid — and, increasingly, as a generic. Here is what one cycle of 21 capsules of 4 mg costs in seven places.
Researched with AI assistance; every figure is checked against the primary source cited on this page before publishing. How we work →
Pomalyst 4 mg (pomalidomide; sold in Europe as Imnovid) is taken once a day on days 1 to 21 of each 28-day cycle for multiple myeloma (FDA label) — so one cycle = 21 capsules, the common European pack. The Dutch list prices per capsule, so we multiply by 21. The two US list figures from CMS are for a “30-day supply” and are shown as published. US dollars at European Central Bank reference rates of November 6, 2026. The price types differ — list price, negotiated price, statutory ceiling, retail price — and are labelled.
POMALYST / IMNOVID / POMALIDOMIDE 4 MG · ONE 28-DAY CYCLE = 21 CAPSULES
Price by country, November 2026
US list price: CMS figure for a 30-day supply (2024). No public pharmacy price in France.
| Country | Official price | 30 days in US dollars | What a patient typically pays |
|---|---|---|---|
| 🇺🇸 United States (list, 2024) | Pomalyst $21,744 for a 30-day supply (CMS, 2024) | $21,744 | — |
| 🇺🇸 United States (Medicare, 2027) | Pomalyst $8,650 negotiated price per 30-day supply, from Jan 1, 2027 (CMS); $434.542696 per capsule | $9,125 per cycle | Depends on the Part D plan and coverage phase |
| 🇩🇪 Germany | Statutory price ceiling (Festbetrag) €2,295.30 for 21 capsules; Imnovid €9,109.45; generics €1,995.34 to €2,875.09 (Festbetrag list, Nov 1, 2026) | $2,563 (Imnovid $10,171) | Co-payment €10 per pack, plus €6,814.15 above the ceiling for Imnovid |
| 🇬🇧 United Kingdom | Generic pomalidomide £7,995.60 to £8,884.00 for 21 capsules (NHS prices); Imnovid £8,884.00, discontinued Feb 9, 2026 | $10,702 (generic) | £9.90 per item in England; free in Scotland, Wales and Northern Ireland |
| 🇨🇭 Switzerland | Imnovid CHF 7,250.95 for 21 capsules; generics CHF 3,029.70 (public prices; limitation) | $8,854 (generic $3,700) | 40% share for Imnovid, 10% for a generic, after the annual deductible |
| 🇦🇹 Austria | Imnovid not listed; generics €354.00 to €702.95 for 21 capsules (social-insurance prices excl. VAT) | generic $395 | €7.55 prescription fee per pack; for specified uses |
| 🇳🇱 Netherlands | Imnovid €235.70 per capsule; generic (Krka) €210.21 (average pharmacy prices) | $5,526 (generic $4,929) | Fully reimbursed; counts toward the annual deductible |
| 🇫🇷 France | Imnovid and generics listed without a pharmacy price in the public medicines database | — | — |
We compare prices; we do not recommend where to buy medicine. Cancer treatment decisions belong with your oncology team.
The $8,650 is the price Medicare negotiated under the Inflation Reduction Act for a 30-day supply, effective January 1, 2027. CMS’s data file sets $434.542696 per capsule for every strength, so one 21-capsule cycle comes to $9,125 (our calculation). In 2024 about 14,000 people with Medicare Part D used Pomalyst, and Part D spent $2.15 billion on it before rebates (CMS). The US pharmacy price survey (NADAC, November 4, 2026) lists no pomalidomide.
Statutory health insurance pays up to the Festbetrag of €2,295.30 for 21 capsules of 4 mg. Imnovid is listed at €9,109.45 (one further Imnovid pack at €1,995.20), so for that pack patients would pay the €6,814.15 difference on top of the co-payment; generics listed from €1,995.34 stay within the ceiling (Festbetrag list, November 1, 2026). The co-payment is 10% of the price, at most €10 — from January 1, 2027 at most €15 (Federal Law Gazette).
Austria lists generic pomalidomide 4 mg from €354.00 for 21 capsules — about $395, or 2% of the 2024 US list price (our calculation: $395 ÷ $21,744). The German ceiling of €2,295.30 (about $2,563) is 12% of it (our calculation: $2,563 ÷ $21,744). Brand Imnovid stays expensive where it is still listed: CHF 7,250.95 in Switzerland and €235.70 per capsule in the Netherlands.
CMS recorded a US list price of $21,744 for a 30-day supply in 2024; Medicare’s negotiated price from January 1, 2027 is $8,650 (CMS), or $9,125 for one 21-capsule cycle at $434.54 per capsule (our calculation). In Europe, 21 capsules of 4 mg cost from €354.00 (generic, Austria) to €9,109.45 (Imnovid, Germany); the German statutory ceiling is €2,295.30.
Both contain pomalidomide; Imnovid is the name used in Europe. In the UK the Imnovid pack was discontinued on February 9, 2026, and generic pomalidomide is listed instead (dm+d).
In Europe, yes: Austria lists generics from €354.00 for 21 capsules of 4 mg, Germany from €1,995.34, Switzerland at CHF 3,029.70, the Netherlands from €210.21 per capsule and the UK from £7,995.60. The US pharmacy price survey (NADAC, November 4, 2026) lists no pomalidomide.
Statutory insurance pays up to the Festbetrag of €2,295.30 for 21 capsules. For generics within the ceiling, patients pay only the co-payment (at most €10, from 2027 at most €15); for the Imnovid pack at €9,109.45 they would pay the €6,814.15 difference as well.
Twenty-one: one capsule a day on days 1 to 21 of each 28-day cycle for multiple myeloma (FDA label). For Kaposi sarcoma the label dose is 5 mg on the same schedule.
Wellness Vision does not sell medicine, recommend pharmacies or suppliers, or take payments from drug makers. Every price above comes from the official source cited; currency conversions and 30-day figures are our own calculations, shown with their formula. This is a cost comparison, not medical advice.
You shouldn't have to go broke to feel whole.
